Literature DB >> 33795950

Retinal Nerve Fiber Layer Thickness Correlates with Serum and Cerebrospinal Fluid Neurofilament Levels and is Associated with Current Disability in Multiple Sclerosis.

Cihat Uzunköprü1, Nur Yüceyar2, Suzan Güven Yilmaz3, Filiz Afrashi3, Özgül Ekmekçi2, Dilek Taşkiran4.   

Abstract

INTRODUCTION: The main purpose of the present study is to confirm Peripapillary Retinal Nerve Fiber Layer (pRNFL) thickness is a biomarker of axonal degeneration in patients with Multiple Sclerosis (MS) and to evaluate its relationship with Neurofilament heavy chain (NfH) and Nitrotyrosine (NT).
METHOD: We quantified serum (s) and/or cerebrospinal fluid (CSF) NfH and NT levels in 30 relapsing-remitting MS patients (RRMS), 16 secondary progressive MS (SPMS) patients and in 29 control subjects matched for age and gender. Optical coherence tomography (OCT) measurements of pRNFL were performed in all subjects. Clinical outcomes were tested by Multiple Sclerosis Functional Composite (MSFC) and Expanded Disability Status Scale (EDSS).
RESULTS: RRMS patients exhibited significantly higher NfH/NT levels (99 pg/mL, 107.52 nM respectively) than controls (74 pg/mL, 48.72 nM) in CSF (p<0.0001), but not in sera. SPMS patients had significantly higher s NfH/NT values (111.25 pg/mL, 1251.77 nM respectively) and lower mean pRNFL thickness (79 µm) than patients with RRMS (98.50 µm) and controls (108 µm) (p<0.0001). pRNFL thickness was significantly correlated with all clinical disability measurements (EDSS, Trail Making test, 9-Hole Peg Test, and PASAT) in both RRMS and SPMS (p<0.001, p=0.02, p=0.03, p=0.02 respectively). A positive correlation was also found between serum and/or CSF NfH levels and EDSS scores in RRMS and SPMS (p<0.001, p=0.02 respectively). The pRNFL thickness was also correlated significantly with serum and/or CSF NfH levels but not with s/CSF NT levels in both clinical forms of MS (p<0.01, p<0.001 respectively).
CONCLUSION: The current study demonstrated that both pRNFL and s/CSF NfH are reliable and quantitative biomarkers that correlate with current disease course and cross-sectional measure of disability in patients with MS. Copyright:
© 2021 Turkish Neuropsychiatric Society.

Entities:  

Keywords:  Multiple sclerosis; biomarkers; neurofilaments; nitrotyrosine; optic coherence tomography (OCT); peripapillary retinal nerve fiber layer (pRNFL)

Year:  2021        PMID: 33795950      PMCID: PMC7980712          DOI: 10.29399/npa.27355

Source DB:  PubMed          Journal:  Noro Psikiyatr Ars        ISSN: 1300-0667            Impact factor:   1.339


  29 in total

1.  Trail Making Test A and B: normative data stratified by age and education.

Authors:  Tom N Tombaugh
Journal:  Arch Clin Neuropsychol       Date:  2004-03       Impact factor: 2.813

Review 2.  Optical coherence tomography in multiple sclerosis: a systematic review and meta-analysis.

Authors:  Axel Petzold; Johannes F de Boer; Sven Schippling; Patrik Vermersch; Randy Kardon; Ari Green; Peter A Calabresi; Chris Polman
Journal:  Lancet Neurol       Date:  2010-09       Impact factor: 44.182

Review 3.  Multiple Sclerosis.

Authors:  Daniel S Reich; Claudia F Lucchinetti; Peter A Calabresi
Journal:  N Engl J Med       Date:  2018-01-11       Impact factor: 91.245

4.  Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis.

Authors:  Christian Barro; Pascal Benkert; Giulio Disanto; Charidimos Tsagkas; Michael Amann; Yvonne Naegelin; David Leppert; Claudio Gobbi; Cristina Granziera; Özgür Yaldizli; Zuzanna Michalak; Jens Wuerfel; Ludwig Kappos; Katrin Parmar; Jens Kuhle
Journal:  Brain       Date:  2018-08-01       Impact factor: 13.501

5.  Serum neurofilament light chain in early relapsing remitting MS is increased and correlates with CSF levels and with MRI measures of disease severity.

Authors:  Jens Kuhle; Christian Barro; Giulio Disanto; Amandine Mathias; Charlotte Soneson; Guillaume Bonnier; Özguer Yaldizli; Axel Regeniter; Tobias Derfuss; Mathieu Canales; Myriam Schluep; Renaud Du Pasquier; Gunnar Krueger; Cristina Granziera
Journal:  Mult Scler       Date:  2016-01-11       Impact factor: 6.312

6.  Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis.

Authors:  Jens Kuhle; Giulio Disanto; Johannes Lorscheider; Tracy Stites; Yu Chen; Frank Dahlke; Gordon Francis; Anupama Shrinivasan; Ernst-Wilhelm Radue; Gavin Giovannoni; Ludwig Kappos
Journal:  Neurology       Date:  2015-03-25       Impact factor: 9.910

7.  Glial and neuronal markers in cerebrospinal fluid predict progression in multiple sclerosis.

Authors:  M Alba Mañé Martínez; Bob Olsson; Laura Bau; Elisabet Matas; Álvaro Cobo Calvo; Ulf Andreasson; Kaj Blennow; Lucia Romero-Pinel; Sergio Martínez-Yélamos; Henrik Zetterberg
Journal:  Mult Scler       Date:  2015-03-02       Impact factor: 6.312

Review 8.  Molecular biomarkers in multiple sclerosis.

Authors:  Tjalf Ziemssen; Katja Akgün; Wolfgang Brück
Journal:  J Neuroinflammation       Date:  2019-12-23       Impact factor: 8.322

Review 9.  Neurofilaments in progressive multiple sclerosis: a systematic review.

Authors:  Thomas Williams; Henrik Zetterberg; Jeremy Chataway
Journal:  J Neurol       Date:  2020-05-23       Impact factor: 4.849

10.  Biomarker report from the phase II lamotrigine trial in secondary progressive MS - neurofilament as a surrogate of disease progression.

Authors:  Sharmilee Gnanapavan; Donna Grant; Steve Morant; Julian Furby; Tom Hayton; Charlotte E Teunissen; Valerio Leoni; Monica Marta; Robert Brenner; Jacqueline Palace; David H Miller; Raj Kapoor; Gavin Giovannoni
Journal:  PLoS One       Date:  2013-08-01       Impact factor: 3.240

View more
  2 in total

1.  Retinal imaging with optical coherence tomography in multiple sclerosis: novel aspects.

Authors:  Elisabeth Olbert; Walter Struhal
Journal:  Wien Med Wochenschr       Date:  2022-03-28

2.  Phosphorylated Neurofilament Heavy Chain (pNFH) in Clinically Isolated Syndrome and Multiple Sclerosis.

Authors:  Erdem Tüzün; Elif Şanli; Ece Akbayir; Recai Türkoğlu
Journal:  Noro Psikiyatr Ars       Date:  2021-11-15       Impact factor: 1.339

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.